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Abstract
Background: Secondary prevention improves survival, yet implementation is suboptimal. We tested the impact
of a systematic hospital-based educational intervention vs. usual care to improve rates of adherence to secondary
prevention guidelines among women hospitalized with coronary heart disease (CHD), according to their ethnic
status.
Methods: Women (n¼ 304, 52% minorities) hospitalized with CHD were randomly assigned to a systematic
secondary prevention educational intervention vs. usual care. Adherence to goals for smoking cessation, weight
management, physical activity, blood pressure <140=90 mm Hg, low-density lipoprotein cholesterol (LDL-C)
<100 mg=dL (2.59 mmol=L), and use of aspirin=anticoagulants, beta-blockers, and angiotensin-converting en-
zyme (ACE) inhibitors were assessed at 6 months.
Results: On admission, minority women were less likely than white women to meet the goals for blood pressure
(OR¼ 0.46, 95% CI 0.26-0.80), LDL-C (OR¼ 0.57, CI 0.33-0.94), and weight management (OR¼ 0.40, 95% CI 0.20-
0.82). There was no difference between the intervention and usual care groups in a summary score of goals met
at study completion; however, minority women in the intervention group were 2.4 times more likely (95% CI
1.13-5.03) to reach the blood pressure goal at 6 months compared with minority women in usual care. White
women in the intervention group were 2.86 times more likely (95% CI 1.06-7.68) to report use of beta-blockers at
6 months compared with white women in usual care. In a logistic regression model, the interaction term for
ethnic status and group assignment was significant for achieving the blood pressure goal ( p¼ 0.009).
Conclusions: A healthcare systems approach to educate women about secondary prevention and blood pressure
control may differentially benefit ethnic minority women compared with white women.
Introduction
Secondary prevention strategies for coronary heartdisease (CHD), such as cholesterol and blood pressure
management, have been shown to extend survival and to
reduce recurrent cardiovascular events and the need for re-
vascularization in both men and women.1 Despite the docu-
mented efficacy of risk-reducing strategies, many patients
with CHD do not receive optimal preventive therapy and do
not reach target goals.2–4 Women are less likely than men to
participate in comprehensive secondary prevention programs
or formal cardiac rehabilitation and to meet national stan-
dards for risk factor management.5,6 Moreover, minority
women are less likely than white women to have adequate
risk factor control, despite a greater recurrent CHD event
rate.7 These data underscore the importance of developing
systematic approaches to improve adherence with second-
ary prevention strategies, especially among women of ethnic
minorities.
Prior studies have shown that hospital-based programs to
increase adherence to lifestyle and medical therapy for CHD
prevention have mixed results. Systemwide protocols to ini-
tiate aspirin, beta-blocker, angiotensin-converting enzyme
(ACE) inhibitors, and cholesterol-lowering medication during
hospitalization for an acute CHD event have demonstrated
increased use of some therapies after discharge. Prior studies
provided proof of concept; however, secular trends may have
influenced the results because of the uncontrolled design of
the studies.8,9 Well-designed studies of physician or nurse-
directed case management interventions to improve lifestyle
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and risk factor control have shown benefits among intensive
interventions but not consistently among more moderate in-
terventions that may be more readily implemented in prac-
tice.10–15 Studies to evaluate the impact of systems approaches
in real world settings on the quality of preventive care are
very limited, especially among high-risk and ethnically di-
verse populations.
The purpose of the Secondary Prevention Beyond Hospital
Walls Intervention Trial In Women (WITTI Women) Study
was to evaluate the impact of a systematic educational inter-
vention among women hospitalized with CHD on attainment
of American Heart Association=American College of Cardi-
ology (AHA=ACC) secondary prevention guidelines com-
pared with usual care at 6 months after discharge and to
determine if the effect varied by ethnic status.1,16
Materials and Methods
Subjects
The study was a randomized controlled clinical trial of 304
women with CHD admitted to the NewYork-Presbyterian
Hospital (Columbia and Weill Cornell Campuses) or the
University of North Carolina Health System between October
2001 and February 2003. Inclusion criteria were a diagnosis
of acute myocardial infarction (MI) (ICD-9 410.0), unstable
angina (ICD-9 411.1), stable angina (ICD-9 413.9), prior
CHD (ICD-9 412.0), or a cardiac revascularization procedure
(catheter-based ICD-9 36.0, 36.09, 36.3 or coronary artery
bypass grafting [CABG] 414.02). Exclusion criteria were a life
expectancy of <6 months, pregnancy, non-English or non-
Spanish speaking, and an inability or unwillingness to follow
up or give informed consent. Consent from a physician to
participate was required. The institutional review boards of
each participating institution approved the protocol.
Potential subjects were identified through systematic re-
view of hospital admission logs, operating room schedules,
cardiac catheterization laboratory schedules, and hospital
chart review.
Intervention and usual care
Participants were randomized according to a blocked de-
sign (by site and halfway point to recruitment) using a central
dial-in web-based system to assign subjects to the interven-
tion or usual care group. The intervention group received edu-
cation and counseling by a prevention facilitator=educator
during hospitalization and during phone visits at 2, 4, and
12 weeks and a phone or clinic visit at 6 weeks postdischarge.
Prevention facilitators were nonphysician, nonnurse health
professionals who had formal training in health education,
nutrition, medical technology, or public health and under-
went standardized training by the NewYork-Presbyterian
Hospital Preventive Cardiology Program professional staff.
The initial educational session included 1 hour of struc-
tured counseling before discharge that reviewed smoking,
exercise, nutrition, weight, and blood pressure and choles-
terol goals for secondary prevention based on the AHA=ACC
guidelines and provided information on how to achieve them
based on social learning theory and the five A’s construct (ask,
advise, agree, assist, arrange).1,16–19 Specifically, after comple-
tion of an assessment of secondary prevention goal attain-
ment status, participants received feedback on their goals and
health behaviors. They were advised on recommendations for
behavior change personalized to their specific needs. Preven-
tion facilitators and participants agreed on specific, achievable
goals. Facilitators assisted the participants in developing ac-
tion plans to accomplish their goals and provided referrals as
needed. Dates and times for follow-up visits and phone calls
were arranged at the end of the initial educational session for
the purpose of obtaining feedback, monitoring progress, and
encouraging preventive action.
All patients were encouraged to attend cardiac rehabilita-
tion and to exercise a minimum of 3–5 days=week. The facil-
itator instructed the patient on heart rate guidelines and Borg
perceived exertion levels based on treadmill test results as
outlined by the American College of Sports Medicine’s Guide-
lines for Exercise Testing and Prescription.20 The exercise pre-
scription was tailored to individual preferences, orthopedic
limitations, weather conditions, equipment availability, and
other barriers identified by the prevention facilitator. Body
mass index (BMI) was calculated, and participants were
advised of their BMI and the desirable BMI range of 18.5–
24.9 kg=m2. Nutrition counseling was based on the Third
Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treat-
ment of High Blood Cholesterol in Adults (Adult Treatment
Panel III).21 Participants were advised to reduce saturated
fat intake (<7% of calories=day), reduce dietary cholesterol
(<200 mg=day), moderate alcohol consumption, reduce so-
dium intake, increase fruits and vegetables, and incorporate
low-fat dairy products in their diets. Smoking cessation coun-
seling was initiated in smokers in the hospital using relapse
prevention materials based on the U.S. Department of Health
and Human Services recommendations.22 Patients were en-
couraged to stop smoking and avoid secondhand smoke
and were referred to formal smoking cessation programs as
appropriate. All subjects were informed that use of beta-
blockers, aspirin or antiplatelet agents, and ACE inhibitors
often is recommended for patients with CHD, and criteria for
contraindications were reviewed.1
Before discharge, each subject reviewed a personalized
checklist of prevention goal status with the prevention fa-
cilitator and received an educational booklet in English or
Spanish that discussed each target in detail, including the
rationale for risk factor modification and strategies to attain
each goal. All women in the intervention group were sys-
tematically referred to cardiac rehabilitation and were as-
sisted with locating a program if needed. During follow-up
phone calls, the prevention facilitator systematically inquired
about challenges and barriers to adherence to secondary pre-
vention goals. The prevention facilitator problem solved with
the participant for any goals that were not met at baseline or
attained at each contact point. For example, if a woman could
not attend a formal cardiac rehabilitation program because of
lack of transportation, the prevention facilitator assisted with
finding transportation, or a home-based walking program
was prescribed.
The physicians of participants randomized to the inter-
vention group received standardized progress reports about
personalized goal attainment at discharge and 6 weeks. The
report included the current level of risk factor control and
medication use as well as minimum and optimal targets. A
cover letter to the physicians outlined in bold bullet points a
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list of prevention goals that their patients were currently not
meeting according to AHA=ACC standards.1,16
Definition of adherence to goals
Adherence to eight prevention goals was defined as (1)
complete smoking cessation, (2) blood pressure <140=90 mm
Hg, (3) low-density lipoprotein cholesterol (LDL-C)<100 mg=
dL (<2.59 mmol=L), (4) physical activity at least 30 minutes
three times per week or enrollment in formal cardiac reha-
bilitation, (5) BMI 18.5–24.9 kg=m2 and waist circumference
<35 inches (<88 cm), (6) use of aspirin or clopidogrel or
warfarin if aspirin was contraindicated, (7) use of ACE inhib-
itor unless contraindicated or creatinine >2.0 documented,
and (8) use of beta-blocker unless contraindicated.
Baseline and outcome assessments
Standardized examinations and interviewer-assisted
questionnaires were obtained at baseline to assess adherence
to prevention goals by a trained research assistant. Blood
pressure, height, weight, and waist circumference were de-
termined using standard procedures.23,24 Smoking status was
determined by self-report and validated with exhaled carbon
monoxide levels at 6 weeks and 6 months.25 Lipid levels
drawn within 24 hours of admission were used for the base-
line values, and if they were not available, outpatient mea-
sures within 6 months of admission were documented.
Follow-up lipid and lipoprotein levels were obtained by fin-
gerstick and analyzed using Cholestech (Hayward, CA)
technology or performed locally.26
We encouraged all intervention and control subjects to
have outcome measures determined at their respective clinical
site. Because of the tertiary referral nature of the hospitals and
the real world design of the study, if women could not return
for outcome assessment, local physician records and self-
report were systematically obtained in the control and inter-
vention groups to determine adherence to prevention goals.
Women were called up to three times and sent a letter, and
physicians were contacted by staff to obtain outcome infor-
mation. Electronic hospital records and laboratory data were
also reviewed.
Sample size and statistical analysis
The attainment of secondary prevention goals between the
intervention and usual care groups was the primary objective
of the study and was used to determine the sample size. We
devised a summary score of secondary prevention goals (each
goal attained equal to 1 point) to evaluate overall adherence.
The study was designed to have 80% power to detect a dif-
ference in a mean summary score of 1 between the two
groups, assuming a common standard deviation (SD) of 3.0
(based on pilot data) using a two-group t test and 0.05 two-
sided significance level, assuming an attrition of 5% over a
6-month follow-up period.
The intention-to-treat analysis was a t test comparison of
the summary score at 6 months between the intervention
group and the usual care group. We then stratified by ethnic
status and repeated the analysis at 6 weeks and 6 months.
Potential confounding was evaluated using linear regression
models that included clinical site, education level (>high
school education vs. not), marital status (married vs. unmar-
ried), revascularization status (surgical or nonsurgical vs.
neither), age (65 vs. <65 years), and ethnic status (white
vs. minority) in addition to group assignment. We tested for
interaction using an ethnic statusgroup assignment term
in the model. In secondary analyses, we compared the pro-
portion of women who met each of the eight prevention goals
in the intervention and usual care groups using a chi-square
test. We conducted the analysis for women overall by site and
by CHD diagnosis and stratified by ethnic status; we also
compared proportions of minorities and whites achieving
goals within each treatment arm at 6 months. We performed
logistic regression that included the independent variables
outlined, with each prevention goal (achieved or not) as the
dependent variable. To evaluate the potential impact of
missing data and lost to follow-up, we imputed the 6-month
follow-up summary score with the baseline score (assumed
no change) for each subject and repeated the main analysis.
Statistical analyses were conducted using the SAS version 8.2
(Cary, NC). Statistical significance was set at p< 0.05.
Results
As shown in Figure 1, there were 1150 women approached
to participate, and 536 were excluded, primarily because of an
inability or unwillingness for follow-up. Of the 614 subjects
who were eligible for participation, 50% (n¼ 304) agreed and
signed the informed consent. The reasons for nonparticipa-
tion were (1) felt too old or too sick (n¼ 165), (2) felt no need
for education (n¼ 90), (3) felt too stressed (n¼ 26), (4) were
opposed to research (n¼ 21), or (5) family objected to partic-
ipation (n¼ 8).
At the 6-week and 6-month follow-up visits, 86% and 80%
of subjects, respectively, had outcome measures available for
analysis. Overall, intervention subjects were not more likely
than usual care subjects to have follow-up information avail-
able, although at 6 weeks and 6 months, minorities were more
likely than white women to return for a visit. At 6 months,
56% of the subjects with follow-up data had measurements
determined at the clinical site, and 44% were obtained from
local physician records=self-report that was not differential
with respect to intervention and controls. There was a trend
for higher follow-up rates among those with a history of CHD
prior to admission compared to those with newly diagnosed
CHD (OR¼ 1.4, 95% CI 0.9-2.2).
Baseline characteristics of the study participants are listed
in Table 1. The mean age of women with CHD in this study
was 62.3 12.4 years (range 29–90 years); 47.7% were white,
33.6% were black, and 15.1% were Hispanic. There were no
significant differences in any major characteristic based on
group assignment, suggesting randomization was successful.
Of note was that minority women were significantly less
likely to have an education beyond high school ( p¼ 0.0004) or
be married ( p¼ 0.006) and were significantly more likely to
have a history of diabetes ( p¼ 0.03) or history of hypertension
( p¼ 0.0008), or be <65 years ( p¼ 0.008) on admission com-
pared with white women. Approximately half of the women
were admitted with an acute coronary syndrome, and 55% of
the participants underwent a revascularization procedure
(30% of women had CABG). Overall, 74% of women had a
prior history of CHD documented.
There were no significant differences in baseline preven-
tion goals between the intervention and usual care groups
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(Table 2). Of note is that overall, only 13% of women met the
weight management goal, 20% met the exercise goal, and
less than half (41%) had an optimal LDL-C, <100 mg=dL
(2.59 mmol=L). The intervention group did not differ with
respect to the usual care group for the summary score (mean
goals achieved) at 6 weeks or 6 months, before and after
imputing missing data. The rate of smoking was greater in
the intervention arm compared with the usual care group at
6 months, although both groups had more nonsmokers at
follow-up than at baseline. In a multiple logistic regression
FIG. 1. Study flow diagram.
Table 1. Baseline Characteristics of Women Hospitalized with Coronary Heart Disease,
by Group Assignment and Ethnicity
Group assignment Ethnicity
Intervention Usual care White Minority
(n¼ 151) (n¼ 153) (n¼ 145) (n¼ 159)
Characteristic n (%) n (%) n (%) n (%)
Age  65 years 59 (39) 67 (44) 72 (50) 54 (34)*
White 74 (49) 71 (46) 145 (100) 0 (0)
>High school education 73 (49) 61 (40) 79 (55) 55 (35)*
Married 64 (42) 64 (42) 73 (50) 55 (35)*
With dependents 40 (27) 33 (22) 33 (23) 40 (25)
Employed 39 (26) 35 (23) 38 (27) 36 (23)
Prior history of CHD 106 (70) 118 (77) 106 (73) 118 (74)
Current ACS 73 (48) 72 (47) 77 (53) 68 (43)
Current revascularization 80 (53) 86 (56) 87 (60) 79 (50)
History of DM 63 (42) 68 (44) 53 (37) 78 (49)*
History of hypertension 116 (78) 122 (80) 102 (71) 136 (87)*
History of dyslipidemia 108 (73) 114 (75) 109 (76) 113 (72)
*p< 0.05 between group comparison (white vs. minority).
CHD, coronary heart disease; ACS, acute coronary syndrome; DM, diabetes mellitus.
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model adjusted for confounders, group assignment was not
predictive of smoking status or any other prevention goal at
the 6-month follow-up.
Subgroup analysis by ethnic status is depicted in Figure 2.
Baseline data demonstrate that minority women were sig-
nificantly less likely than white women to meet the goals for
blood pressure (OR¼ 0.46, 95% CI 0.26-0.80), LDL-C (OR¼
0.56, CI 0.33-0.94), and weight management (OR¼ 0.40, 95%
CI 0.20-0.82). A similar pattern was observed at 6 months. In
stratified analyses, white women randomized to the inter-
vention had increased use of beta-blockers at 6 months com-
pared with white controls (OR¼ 2.86, 95% CI 1.06-7.68), and
minority women who received the intervention were more
likely to be at the blood pressure target than minority women
in usual care (OR¼ 2.39, 95% CI 1.13-5.03).
Interestingly, within the intervention arm, minority were
equally likely as white women to meet the eight prevention
goals; however, within the usual care group, white women
were significantly more likely than minority women to reach
target for blood pressure ( p¼ 0.0002) and LDL-C ( p¼ 0.012)
and had a trend toward increased use of aspirin=antiplatelet
agents ( p¼ 0.053). A formal test of interaction between ethnic
status and group assignment was significant for achieving the
blood pressure goal at 6 months ( p¼ 0.009). Among minori-
ties, regression models adjusted for age, education, marital
status, employment, and site reveal that minority women as-
signed to the intervention had a 2.29-fold increased likelihood
of being at blood pressure goal compared with minority
women who received usual care.
Discussion
This controlled study of a systematic hospital-based edu-
cational intervention among high-risk women to improve
adherence to AHA=ACC secondary prevention goals dem-
onstrated that (1) minority women were less likely to meet
national standards for risk factor management upon hospi-
talization, (2) although a systematic educational intervention
was not associated with significant benefits in the overall
study population, minority women who received the inter-
vention had significant improvements in blood pressure
control compared with usual care, and white women who
received the intervention were more likely to use beta-
blockers compared with the usual care group, and (3) secular
trends in the control group showed that rates of nonsmoking,
lipid control, exercise, and use of ACE inhibitors improved
Table 2. Baseline and Follow-up Secondary
Prevention Goals Met Among Women




(n¼ 151) (n¼ 153)
Prevention goal n (%) n (%)
Blood pressure <140=90 mm Hg
Baseline 114 (75) 118 (77)
(n) 151 153
6 weeks 84 (65) 73 (60)
(n) 129 121
6 months 74 (64) 66 (59)
(n) 116 111
LDL-C <100 mg=dL
Baseline 51 (42) 49 (40)
(n) 121 121
6 weeks 36 (45) 48 (58)
(n) 80 83
6 months 54 (57) 50 (60)
(n) 95 84
Nonsmoker
Baseline 119 (79) 131 (86)
(n) 151 153
6 weeks 105 (86) 102 (93)
(n) 122 110
6 months 95 (85) 101 (94)*
(n) 112 108
Exercise=cardiac rehabilitation
Baseline 29 (20) 29 (20)
(n) 144 148
6 weeks 27 (23) 27 (25)
(n) 119 108
6 months 41 (38) 32 (30)
(n) 108 105
BMI 18.5–24.9 kg=m2 and waist circumference <35 inches
Baseline 24 (17) 15 (10)
(n) 143 150
6 weeks 28 (22) 21 (17)
(n) 126 121
6 months 22 (20) 20 (18)
(n) 108 109
Aspirin=antiplatelet therapy
Baseline 127 (85) 133 (88)
(n) 149 151
6 weeks 115 (87) 101 (82)
(n) 132 123
6 months 102 (89) 99 (84)
(n) 115 118
ACE inhibitor therapy
Baseline 93 (67) 98 (66)
(n) 139 149
6 weeks 79 (76) 79 (84)
(n) 104 94
6 months 77 (81) 67 (75)
(n) 95 89
Beta-blocker therapy
Baseline 118 (80) 118 (81)
(n) 147 146
6 weeks 114 (86) 96 (79)
(n) 132 122
6 months 98 (84) 89 (76)
(n) 116 117
Table 2. (Continued)
Summary score Mean SD number of goals attained
Baseline 4.7 (1.2) 4.7 (1.2)
(n) 103 111
6 weeks 4.7 (1.3) 5.1 (1.2)
(n) 59 54
6 months 5.1 (1.1) 5.1 (1.0)
(n) 69 58
*p< 0.05 between group comparison (intervention vs. usual care).
aTo convert values for cholesterol from mg=dL to mmol=L,
multiply by 0.02586. To convert values in inches to centimeters,
multiply by 2.54.
CHD, coronary heart disease; ACE, angiotensin-converting en-
zyme.
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substantially 6 months after hospitalization. Despite the pos-
itive trends, our research documents exceptionally low com-
pliance with lifestyle recommendations.
Our data are consistent with other studies that have eval-
uated modest interventions to improve risk factor control
among patients with CHD.13,15,27 In a randomized trial of 201
patients with an acute coronary event assigned to either case
management with counseling by a physician or usual care,
there were no significant differences in lipids, blood pressure,
glucose, BMI, or number of smokers between the two groups
after 18 months of follow-up.13 Although counseling was
provided by a physician in contrast to a nonphysician as used
in our study, both designs preserved the patient and pri-
mary care physician relationship by providing summarized
reports of progress toward standard goals. Similarly, among
540 smokers hospitalized with CHD, a brief nursing inter-
vention with support and reinforcement was not associated
with greater smoking cessation compared with usual care.15
Among 375 patients with CHD randomized to a nurse-based
educational intervention that focused on patient empower-
ment, knowledge of LDL-C targets increased, but cholesterol
management was not improved compared with a usual care
group of 381 patients 1 year after hospitalization.27 Unlike our
trial, these studies were conducted in primarily white popu-
lations and did not evaluate subgroup interactions.
Interventions that included a nurse practitioner to augment
physician care by providing counseling and prescriptions for
lipid-lowering medications have resulted in improved lipids
and lifestyle factors.11,14 A comprehensive, multifactorial
residential program with systematic maintenance was asso-
ciated with significant improvements in lipid levels, exercise
capacity, and BMI in patients with a recent history of an acute
coronary event or revascularization procedure.28 These data
suggest that interventions more intensive than that we em-
ployed or that have the flexibility to prescribe therapy may be
more effective in improving adherence to secondary preven-
tion goals than educational and patient enabling strategies.
Hospital protocols structured to uniformly prescribe pre-
ventive medications have shown success with improved ad-
herence at discharge; however, most of these have not been
randomized and controlled.8,9,29 The Cardiac Hospitalization
Atherosclerosis Management Program (CHAMP) study was
one of the first attempts to evaluate a systems approach to
improve secondary prevention.8 The intervention focused on
initiation of preventive therapies during hospitalization using
standard algorithms. A before and after CHAMP analysis
showed significant improvement in rates of compliance at
discharge, with a sustained effect of 58% of patients achiev-
ing an LDL goal100 mg=dL (2.59 mmol=L) compared with
6% in the pre-CHAMP period ( p< 0.001). The Guidelines
Applied in Practice (GAP) Initiative showed that an inter-
vention using standard orders, clinical pathways, pocket
guides, chart stickers, performance charts, and patient infor-
mation and discharge forms increased rates of aspirin use but
not other preventive care quality indicators in participating
hospitals compared with hospitals that volunteered for the
program but were not selected.9 A decentralized chest pain
unit with standardized optional admission orders for aspirin,
beta-blockers, ACE inhibitor, and statin therapy significantly
increased rates of statin therapy at discharge compared with
the pre-intervention period.29 A lack of significant improve-
ment in other preventive medications may have reflected high
baseline rates of use. Likewise, in our study, the majority of
women admitted were prescribed aspirin=antiplatelet ther-
apy, beta-blockers, and ACE inhibitors, and the lack of impact
of our intervention may also have been due to a ceiling effect.
Our baseline data documenting that minority women with
CHD are less likely to meet preventive standards than are
white women are consistent with data from the Heart and
Estrogen=Progestin Replacement Study (HERS) showing
black women with CHD had higher rates of hypertension,
diabetes, and hypercholesterolemia and were less likely to
receive aspirin and statins than white women.7 The HERS
analysis was limited to postmenopausal black women and
recruited subjects between 1993 and 1994. Our recruitment
occurred nearly 10 years later and extends their findings to a
more diverse and contemporary cohort.
The results of our analysis between minority and white
women suggested that there was a differential impact of the
intervention between subpopulations related to blood pres-
FIG. 2. Proportion of white and minority women achieving secondary prevention goals at 6 months, by group assignment.
BP, blood pressure; LDL, low-density lipoprotein; ASA, antiplatelet=anticoagulant therapy; ACE, angiotensin-converting
enzyme inhibitor therapy; BB, beta-blocker therapy.
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sure control and medication adherence. The observation that
6-month blood pressure levels were worse than baseline levels
for all groups should be interpreted with caution, as many
patients were treated aggressively during hospitalization for
an acute event, and lower baseline blood pressure likely re-
flects intensive monitoring and treatment with blood pressure
medication or sedatives during hospitalization. It may also be
reflective of the finding that sicker women (i.e., participants
with a documented history of CHD) were more likely to
complete the trial. We hypothesize that less access to care
among minorities and poorer background rates of preventive
care may have enhanced the efficacy of our intervention in
this population. A meta-analysis of cardiac education pro-
grams prior to 1990 demonstrated a measurable impact on
blood pressure and other risk factors related to lifestyle.30
These studies were conducted before the release of many
major prevention trials and suggest that education interven-
tions to improve risk factor control may be useful against a
background of minimal preventive medical management,
lending support to a differential impact among minorities in
our study, where lower rates of preventive care were clearly
documented.
A major strength of our trial was the high participation rate,
with >50% representation by minorities; however, our study
had limitations. We had poor rates of compliance with return
visits and did not have complete data available on a sub-
stantial proportion of subjects. Although the follow-up was
nondifferential with respect to group assignment, our power
to demonstrate a significant impact of the intervention was
reduced; however, several positive trends were observed. In-
complete data are a common problem in lifestyle intervention
trials, and there are no adequate analytic methods to address
the problem that do not introduce potential bias.31 Therefore,
we maintained an intention-to-treat approach to the analysis.
Not all subjects had follow-up measurements conducted at
the clinical site, but given the real world nature of the study,
the outcomes assessed by local physicians were important.
Moreover, the categorical nature of prevention goals makes it
unlikely that measurement error would lead to significant
change in goal status. The likelihood of differential misclas-
sification is small because rates of central and local measure-
ments were similar between intervention and usual care
groups. The difficulty in having subjects return for follow-up
in our study despite multiple attempts underscores the chal-
lenges of studies that include older women and ethnic mi-
norities. Barriers to follow-up should be addressed in future
research, as this may have important implications for clinical
outcomes in high-risk populations.
Conclusions
We demonstrated that minority women hospitalized with
CHD are less likely than white women to meet national
standards for prevention and that a systematic intervention
to improve secondary prevention guideline adherence was
not significantly better than usual care for women overall at
6 months, although minority women benefited to a greater
degree than white women with respect to blood pressure
control. CHD remains the leading killer of women and dis-
proportionately affects minorities, as does hypertension.32,33
The AHA has recently published professional and lay
Evidence-Based Guidelines for the Prevention of Cardiovas-
cular Disease in Women to help physicians and the public
improve lifestyle and risk factor control.34 Our findings sug-
gest that education about prevention and the guidelines is
particularly important among ethnic minorities.
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